Related references
Note: Only part of the references are listed.HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
Ulla Wilking et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis
Nikolas H. Stoecklein et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients
Bent Ejlertsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Li Ding et al.
NATURE (2010)
Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification
Matteo Brunelli et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
C. Liedtke et al.
ANNALS OF ONCOLOGY (2009)
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
C. Simmons et al.
ANNALS OF ONCOLOGY (2009)
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2009)
HER-2/neu expression in primary and metastatic breast cancer
Elyse E. Lower et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2009)
Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?
Eitan Amir et al.
LANCET ONCOLOGY (2009)
Parallel progression of primary tumours and metastases
Christoph A. Klein
NATURE REVIEWS CANCER (2009)
Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer:: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization
A. D. Graham et al.
HISTOPATHOLOGY (2008)
Technical pitfalls potentially affecting diagnoses in immunohistochemistry
G. Bussolati et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: Impact on patient management
Valentina Guarneri et al.
ONCOLOGIST (2008)
Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays
Katrine L. Henriksen et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases
Lurdes Torres et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis
Mario R. D'Andrea et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer
Lyndsay N. Harris et al.
CLINICAL CANCER RESEARCH (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer
J Hurley et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
AS Knoop et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
J Zidan et al.
BRITISH JOURNAL OF CANCER (2005)
Effect of heat-induced antigen retrieval following inconsistent formalin fixation
T Boenisch
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2005)
Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
Y Gong et al.
CANCER (2005)
Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
MC Gutierrez et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Change of HER-2/neu status in a subset of distant metastases from breast carcinomas
P Regitnig et al.
JOURNAL OF PATHOLOGY (2004)
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study
HJ Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
D Gancberg et al.
ANNALS OF ONCOLOGY (2002)
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma
D Gancberg et al.
JOURNAL OF CLINICAL PATHOLOGY (2002)
Evaluation of HER2, p53, bcl-2, topoisomerase II-α, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes
F Cardoso et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
